key: cord-1046805-g0lh3pkb
authors: Bloomfield, Marketa; Parackova, Zuzana; Hanzlikova, Jana; Lastovicka, Jan; Sediva, Anna
title: Immunogenicity and Safety of COVID-19 mRNA Vaccine in STAT1 GOF Patients
date: 2021-10-31
journal: J Clin Immunol
DOI: 10.1007/s10875-021-01163-8
sha: 97a718fdb802ba58c083016bcddb32aba9b9771c
doc_id: 1046805
cord_uid: g0lh3pkb

nan

Hypothetically, STAT1 GOF patients may be to some degree protected from SARS-CoV-2 infection/severe COVID-19 via the pre-emptive overactivation of IFN-I signaling, despite their otherwise immune deficient status. On the other hand, abnormally augmented IFN response may contribute to the catastrophic cytokine-driven hyperinflammation in delayed stages of COVID-19 [10] . So far, three STAT1 GOF patients were reported to suffer COVID-19 (one on ruxolitinib), all experiencing a mild course [11] [12] [13] .

The mRNA-based SARS-CoV-2 vaccines activate the mechanisms of innate immunity, resulting in the production of multiple inflammatory mediators, including IFNs, which effectively promote both T and B cell-mediated response and antigen-specific immune memory [14] . The introduction of such agents into an IFN-biased environment in STAT1 GOF might amplify the immune dysregulation-related symptoms. Conversely, STAT1 GOF patients receiving JAK inhibitors, such as ruxolitinib, may have blunted vaccine response, due to the artificially suppressed JAK/STAT pathway. Recently, two STAT1 GOF CMC patients were reported to mount a normal vaccine-specific anti-spike 1 antibody response and one who failed to do so [15, 16] .

Here, we report seven adult STAT1 GOF patients (two with novel mutations) with an uneventful course of COVID-19 vaccination, and/or SARS-CoV-2 infection, including two patients receiving JAK inhibitor ruxolitinib.

Seven adult Czech STAT1 GOF CMC patients (previously described p.Y68C, p.A267V, p.M390T and novel p.T288N and p.E29A; cohort characteristics detailed in Supplementary Table 1 ) received SARS-CoV-2 spike 1 protein-encoding mRNA vaccine (Comirnanty®, Pfizer/BioNTech). All seven received two doses, six of them 3 to 6 weeks apart, one patient 4 months apart. Two patients were receiving ruxolitinib at the time of vaccination. No adverse events were noted during 1-4-month follow-up. The antibody response was determined prior to the vaccination (Enzyme immunoassay COVID-19 RBD by TestLine Clinical Diagnostics, Czech Republic) and 3-5 weeks after the second vaccine dose (Microblot-Array COVID-19 by TestLine Clinical Diagnostics, Czech Republic). Four seronegative patients achieved vaccine-specific receptor-binding domain spike protein (RBD) IgG seroconversion (median 1211.5, range 999-1347 U/ml), which was comparable to vaccinated healthy controls (N = 100, median 985.5, range 470-1924 U/ml). Only two patients responded with anti-RBD IgA, compared to 76 out of 100 healthy controls. This may be an important efficacy parameter, as serum IgA was shown to be an early SARS-CoV-2-neutralizing agent [17] . Despite the absence of any previous COVID-19 symptoms, one patient (P5 M390T ) was found to be S1-spike protein seropositive before vaccination, and one patient (P4 A267V , unavailable for testing prior to vaccination) had anti-nucleocapsid, as well as anti-RBD antibodies after vaccination, suggestive of past infections in both patients. One patient did not mount an antibody response after vaccination (P7 E29A ) (Fig. 1A) . Regardless of the serologic status, six out of seven patients (one patient not tested), including the two ruxolitinib receivers, were found to mount a virus-specific (S1-spike protein) cellular immune response (median 1192.5, range 585-4115 mIU/ml), which was comparable to vaccinated healthy controls (N = 7, median 1830, range 675-1735 mIU/ ml), detected by whole blood IFN-γ release assay (EURO-IMMUN SARS-CoV-2 IGRA, Germany) (Fig. 1B) . The summary of the humoral and cellular COVID-19-related immune parameters is listed in Table 1 .

Within the cohort, two patients were of particular interest. An 18-year-old female P5 M390T with CMC and severe pulmonary damage had asymptomatic COVID-19 infection, as evident by anti-S1 seropositivity prior to vaccination. Despite that, the anti-nucleocapsid antibodies were not detectable. This patient has been on ruxolitinib (0.4 mg/ kg/day, dose titered to healthy control's phosphorylated STAT1 level) for the past 6 months; however, it is unknown whether the infection occurred prior or after the JAK inhibitor initiation.

The second patient, a 45-year-old male P7 E29A with CMC, severe pneumopathy, and multiple autoimmune phenomena, was vaccinated while COVID-19 naïve and 5 months on ruxolitinib (0.2 mg/kg/day, dose titered to healthy control's phosphorylated STAT1 level). The patient failed to produce detectable SARS-CoV-2 antibodies. However, this may be attributed to continuing B cell impairment after previous CD20-depletion therapy (rituximab) 18 months prior to vaccination; while the overall CD19 B cells count represented 5.7% of lymphocytes, the B cell pool constituted predominantly of CD27 negative naïve B cells prior to vaccination. In fact, such skewed antibody response to primary antigen exposure post-rituximab has been reported by multiple studies, including, recently, the impaired response to SARS-CoV-2 vaccines [16, 18] . Nevertheless, the patient developed a strong S1-peptide-specific T cell immune response in IGRA, interestingly, the strongest in our cohort (4115 mIU/ml; Fig. 1B ).

In summary, while limited by the cohort size and the absence of antibody-neutralization assays, our observations indicate that SARS-CoV-2 mRNA vaccination in Fig. 1 Immune responses to SARS-CoV-2 mRNA vaccine (Pfizer/BioNTech) in STAT1 GOF patients evaluated 3-5 weeks after the second vaccine dose. A Antibody titers in 7 patients determined by Microblot-Array COVID-19 (TestLine Clinical Diagnostics, Brno, Czech Republic); results are compared to vaccinated healthy controls (N = 100) and considered positive if value is > 210 U/ ml. B S1-spike protein-specific T cell immune response in 6 patients determined by EURO-IMMUN SARS-CoV-2 IGRA, Lübeck, Germany; results are compared to vaccinated healthy controls (N = 7) and considered positive if value > 200 mIU/ml. CMC, chronic mucocutaneous candidiasis; RBD, receptorbinding domain spike protein; S1, spike 1 protein STAT1 GOF is immunogenic and may be safe, even during treatment with JAK inhibitor and after past infection. Furthermore, we affirm that COVID-19 disease may take a mild/asymptomatic course in STAT1 GOF CMC. This data may help guide clinical counselling for patients with STAT1 GOF CMC. 

Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype

Gain-of-function STAT1 mutations impair STAT3 activity in patients with chronic mucocutaneous candidiasis (CMC)

Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations

Human coronaviruses: a review of virus-host interactions

Toll-like receptors and the control of immunity

Type i interferons: distinct biological activities and current applications for viral infection

Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science (80-)

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science (80-)

COVID-19 treatment guidelines: do they really reflect best medical practices to manage the pandemic?

Retrospective multicenter cohort study shows early interferon therapy is associated with favorable clinical responses in COVID-19 patients

SARS-CoV-2 infection in a pediatrics STAT1 GOF patient under ruxolitinib therapy-a matter of balance?

Coronavirus disease 2019 in patients with inborn errors of immunity: an international study

COVID-19 in patients with primary immunodeficiency

mRNA vaccinesa new era in vaccinology

Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity

Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity

IgA dominates the early neutralizing antibody response to SARS-CoV-2

SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity